OPKO Health Gestione

Gestione criteri di controllo 2/4

OPKO Health Il CEO è Phil Frost, nominato in Mar2007, e ha un mandato di 17.67 anni. la retribuzione annua totale è $ 2.28M, composta da 42.2% di stipendio e 57.8% di bonus, comprese azioni e opzioni aziendali. possiede direttamente 35.96% delle azioni della società, per un valore di € 370.06M. La durata media del mandato del team dirigenziale e del consiglio di amministrazione è rispettivamente 9.7 anni e 15.6 anni.

Informazioni chiave

Phil Frost

Amministratore delegato

US$2.3m

Compenso totale

Percentuale dello stipendio del CEO	42.2%
Mandato del CEO	17.7yrs
Proprietà del CEO	36.0%
Durata media del management	9.7yrs
Durata media del Consiglio di amministrazione	15.6yrs

Aggiornamenti recenti sulla gestione

Recent updates

Analisi delle retribuzioni degli amministratori delegati

Come è cambiata la remunerazione di Phil Frost rispetto agli utili di OPKO Health?
Data	Compenso totale	Stipendio	Guadagni aziendali
Sep 30 2024	n/a	n/a	-US$134m
Jun 30 2024	n/a	n/a	-US$243m
Mar 31 2024	n/a	n/a	-US$252m
Dec 31 2023	US$2m	US$960k	-US$189m
Sep 30 2023	n/a	n/a	-US$208m
Jun 30 2023	n/a	n/a	-US$209m
Mar 31 2023	n/a	n/a	-US$291m
Dec 31 2022	US$972k	US$960k	-US$328m
Sep 30 2022	n/a	n/a	-US$317m
Jun 30 2022	n/a	n/a	-US$202m
Mar 31 2022	n/a	n/a	-US$117m
Dec 31 2021	US$2m	US$960k	-US$30m
Sep 30 2021	n/a	n/a	US$76m
Jun 30 2021	n/a	n/a	US$71m
Mar 31 2021	n/a	n/a	US$121m
Dec 31 2020	US$2m	US$960k	US$31m
Sep 30 2020	n/a	n/a	-US$114m
Jun 30 2020	n/a	n/a	-US$200m
Mar 31 2020	n/a	n/a	-US$293m
Dec 31 2019	US$1m	US$960k	-US$315m
Sep 30 2019	n/a	n/a	-US$279m
Jun 30 2019	n/a	n/a	-US$244m
Mar 31 2019	n/a	n/a	-US$191m
Dec 31 2018	US$2m	US$960k	-US$153m
Sep 30 2018	n/a	n/a	-US$295m
Jun 30 2018	n/a	n/a	-US$303m
Mar 31 2018	n/a	n/a	-US$314m
Dec 31 2017	US$971k	US$960k	-US$305m

Compensazione vs Mercato: La retribuzione totale di Phil ($USD 2.28M ) è superiore alla media delle aziende di dimensioni simili nel mercato German ($USD 1.46M ).

Compensazione vs guadagni: La retribuzione di Phil è aumentata nonostante l'azienda non sia redditizia.

AMMINISTRATORE DELEGATO

Phil Frost (88 yo)

17.7yrs

Mandato

US$2,277,200

Compensazione

Dr. Phillip Frost, also known as Phil, M.D., Ph D., is Director of Non-Invasive Monitoring Systems, Inc. since June 01, 2023. He has been the Chairman, Chief Executive Officer and Director of OPKO Health,...

Gruppo dirigente

Nome	Posizione	Mandato	Compensazione	Proprietà
Phillip Frost	Chairman & CEO	17.7yrs	US$2.28m	35.96% € 370.1m
Jane Hsiao	Vice Chairman & Chief Technical Officer	17.8yrs	US$2.19m	4.85% € 50.0m
Elias Zerhouni	President & Vice Chairman	2.5yrs	US$2.19m	2.99% € 30.8m
Adam Logal	Senior VP	17.7yrs	US$1.81m	0.026% € 270.2k
Steven Rubin	Executive VP of Administration & Director	17.5yrs	US$1.94m	0.91% € 9.3m
Akhtar Ashfaq	Senior Vice President of Clinical Research & Development and Medical Affairs - Opko Renal	7.7yrs	Nessun dato	Nessun dato
Gary Nabel	Chief Innovation Officer & Director	2.5yrs	Nessun dato	5.91% € 60.8m
Giovanni Abbadessa	Chief Medical Officer	less than a year	Nessun dato	Nessun dato
Charles Bishop	Chief Executive Officer of OPKO Renal	11.7yrs	Nessun dato	Nessun dato
Antonio Cruz	President of Transition Therapeutics	no data	Nessun dato	Nessun dato
Hans Berner	President of OPKO Health Iberoamerica	no data	Nessun dato	Nessun dato
Damien Burke	Chief Executive Officer of EirGen Pharma	5yrs	Nessun dato	Nessun dato

9.7yrs

Durata media

71.5yo

Età media

Gestione esperta: Il team dirigenziale di XCY è esperto e expertise (durata media dell'incarico 9.7 anni).

Membri del Consiglio di amministrazione

Nome	Posizione	Mandato	Compensazione	Proprietà
Phillip Frost	Chairman & CEO	17.7yrs	US$2.28m	35.96% € 370.1m
Jane Hsiao	Vice Chairman & Chief Technical Officer	17.8yrs	US$2.19m	4.85% € 50.0m
Elias Zerhouni	President & Vice Chairman	2.5yrs	US$2.19m	2.99% € 30.8m
Steven Rubin	Executive VP of Administration & Director	17.8yrs	US$1.94m	0.91% € 9.3m
Gary Nabel	Chief Innovation Officer & Director	2.5yrs	Nessun dato	5.91% € 60.8m
Roger Medel	Independent Director	3.9yrs	US$69.90k	0% € 0
Richard Pfenniger	Lead Independent Director	16.8yrs	US$134.80k	0.048% € 490.1k
Richard Krasno	Independent Director	7.8yrs	US$92.40k	0.015% € 155.8k
John Paganelli	Independent Director	20.9yrs	US$84.90k	0.058% € 593.4k
Prem Lachman	Independent Director	3.7yrs	US$92.40k	0% € 0
Lin-Tsing Yu	Independent Director	15.6yrs	US$62.40k	0.0097% € 100.2k

15.6yrs

Durata media

77yo

Età media

Consiglio di amministrazione esperto: Il consiglio di amministrazione di XCY è composto da personale esperto e esperto (durata media dell'incarico 15.6 anni).

OPKO Health Gestione

Gestione criteri di controllo 2/4

Informazioni chiave

Aggiornamenti recenti sulla gestione

Chairman & CEO recently bought €917k worth of stock

OPKO Health, Inc., Annual General Meeting, Mar 28, 2024

Chairman & CEO recently bought €1.4m worth of stock

President & Vice Chairman recently bought €469k worth of stock

Chairman & CEO recently bought €1.2m worth of stock

Chairman & CEO recently bought €245k worth of stock

Recent updates

OPKO Health, Inc. Provides Financial Guidance for the Fourth Quarter 2024

OPKO Health, Inc. to Report Q3, 2024 Results on Nov 07, 2024

Second quarter 2024 earnings released: US$0.015 loss per share (vs US$0.026 loss in 2Q 2023)

OPKO Health, Inc. to Report Q2, 2024 Results on Aug 07, 2024

OPKO Health, Inc. (NasdaqGS:OPK) announces an Equity Buyback for $100 million worth of its shares.

OPKO Health, Inc. announced that it has received $250 million in funding from Healthcare Royalty Management, LLC

OPKO Health, Inc. announced that it has received $250 million in funding from Healthcare Royalty Management, LLC

Entera Bio Announces Robust Pharmacokinetic Data for First-In-Class Oral Glp-2 Peptide Tablet Treatment for Patients with Short Bowel Syndrome

OPKO Health, Inc. announced delayed annual 10-K filing

New major risk - Financial position

Full year 2023 earnings released: US$0.25 loss per share (vs US$0.46 loss in FY 2022)

Chairman & CEO recently bought €917k worth of stock

OPKO Health, Inc. to Report Q4, 2023 Results on Feb 27, 2024

OPKO Health, Inc., Annual General Meeting, Mar 28, 2024

Chairman & CEO recently bought €1.4m worth of stock

President & Vice Chairman recently bought €469k worth of stock

New minor risk - Profitability

Chairman & CEO recently bought €1.2m worth of stock

New minor risk - Profitability

Third quarter 2023 earnings released: US$0.11 loss per share (vs US$0.12 loss in 3Q 2022)

OPKO Health, Inc. Presents Late-Breaking Clinical Data on RAYALDEE Extended-Release Calcifediol

OPKO Health, Inc. to Report Q3, 2023 Results on Nov 06, 2023

OPKO Health, Inc. to Report Q2, 2023 Results on Aug 03, 2023

Chairman & CEO recently bought €245k worth of stock

Chairman & CEO recently bought €1.1m worth of stock

OPKO Health, Inc. to Report Q4, 2022 Results on Feb 23, 2023

OPKO Health, Inc. to Report Q3, 2022 Results on Nov 08, 2022

Chairman & CEO recently bought €213k worth of stock

Chairman & CEO recently bought €499k worth of stock

OPKO Health, Inc. Announces Leadership Changes for Bioreference Laboratories

Chairman & CEO recently bought €790k worth of stock

OPKO Health, Inc. Provides Revenue Guidance for the Year 2022

Second quarter 2022 earnings released: US$0.14 loss per share (vs US$0.025 loss in 2Q 2021)

OPKO Health, Inc. to Report Q2, 2022 Results on Aug 04, 2022

Chairman & CEO recently bought €227k worth of stock

OPKO Health, Inc., Annual General Meeting, Jul 14, 2022

Chairman & CEO recently bought €1.1m worth of stock

OPKO Health, Inc. (NasdaqGS:OPK) acquired ModeX Therapeutics, Inc. for $300 million.

OPKO Health, Inc. to Report Q1, 2022 Results on May 09, 2022

Chairman & CEO recently bought €97k worth of stock

Chairman & CEO recently bought €2.1m worth of stock

Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat

OPKO Health, Inc. Provides Revenue Guidance for the Year 2022

Chairman & CEO recently bought €269k worth of stock

OPKO Health, Inc. to Report Q4, 2021 Results on Feb 24, 2022

Chairman & CEO recently bought €405k worth of stock

OPKO Health, Inc. Announces That Vifor Fresenius Medical Care Renal Pharma has Initiated the Commercial Launch of Rayaldee® in Germany

Chairman & CEO recently bought €923k worth of stock

Investor sentiment deteriorated over the past week

Japan’s MHLW Approves Pfizer and OPKO’s NGENLA® (Somatrogon), a New Long-Acting Treatment for Pediatric Growth Hormone Deficiency

Sema4 Holdings Corp. (NasdaqGS:SMFR) entered into an agreement to acquire GeneDx, Inc. from OPKO Health, Inc. (NasdaqGS:OPK) for approximately $620 million.

OPKO Health, Inc. Announces Topline Results from Phase 2 Trial Evaluating RAYALDEE to Treat Symptomatic COVID-19 Outpatients

Investor sentiment improved over the past week

Opko Health Receives U.S. FDA Approval for the 4Kscore Test

Investor sentiment deteriorated over the past week

Third quarter 2021 earnings released: EPS US$0.044 (vs US$0.037 in 3Q 2020)

Pfizer and OPKO Announce Extension of U.S. FDA Review of Biologics License Application of Somatrogon for Pediatric Growth Hormone Deficiency

Chairman & CEO recently bought €293k worth of stock

Chairman & CEO recently bought €313k worth of stock

Second quarter 2021 earnings released: US$0.025 loss per share (vs US$0.053 profit in 2Q 2020)

Chairman & CEO recently bought €597k worth of stock

Chairman & CEO recently bought €1.2m worth of stock

Investor sentiment deteriorated over the past week

Chairman & CEO recently bought €82k worth of stock

First quarter 2021 earnings released: EPS US$0.048 (vs US$0.092 loss in 1Q 2020)

Chairman & CEO recently bought €985k worth of stock

New 90-day low: €3.30

OPKO Health, Inc. Announces Appointment of Prem A. Lachman as Director

EMA Accepts Marketing Application of Pfizer Inc. and OPKO Health Inc. for Somatrogon to Treat Pediatric Patients with Growth Hormone Deficiency